Mouse Model News and Research

RSS

Biosynthetic polyphenol may improve cognitive function in Alzheimer's disease patients

Mount Sinai School of Medicine researchers have succeeded in developing a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer's disease (AD). The findings, published in a recent issue of the Journal of Neuroscience, provide insight in determining the feasibility of biosynthetic polyphenols as a possible therapy for AD in humans, a progressive neurodegenerative disease for which there is currently no cure.

2 May 2012

Lenalidomide and SNS01-T combination effective against multiple myeloma

Senesco Technologies, Inc. announced today that a high level of tumor eradication in a mouse model of human multiple myeloma was achieved with a combination of SNS01-T and lenalidomide.

2 May 2012

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.

30 Apr 2012

Cedars-Sinai scientist receives ALS Association Golden West Chapter Commitment to a Cure Award

Robert H. Baloh, MD, PhD, director of Cedars-Sinai Medical Center's Neuromuscular Division, has received the ALS Association Golden West Chapter Commitment to a Cure Award.

30 Apr 2012

Kras gene triggers metabolic changes that fuel cancer cells

Researchers at Dana-Farber Cancer Institute have shown that advanced pancreatic cancers in mice can't survive without continued expression of a mutant oncogene that "rewires" key metabolic pathways to fuel the cancer cells.

27 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Beta cells from genetically modified pigs can effectively restore pancreas function

Transplantation of a whole pancreas or isolated insulin-producing beta cells are the only therapy to cure type 1 diabetes. However, the shortage of organ donors limits this approach to only few patients. LMU researchers have now shown that beta cells from genetically modified pigs can effectively restore pancreas function and can protect porcine beta cells from immune rejection in animal models.

23 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Study shows how cocaine changes the shape and size of neuron rewards in mouse model

New research from Mount Sinai Medical Center in New York reveals that repeated exposure to cocaine decreases the activity of a protein necessary for normal functioning of the brain's reward system, thus enhancing the reward for cocaine use, which leads to addiction. Investigators were also able to block the ability of repeated cocaine exposure, to induce addiction.

23 Apr 2012

First study to quantify effects of AD plaques on brain networks in animal model

Scientists studying the way Alzheimer's takes root in the brain have identified important new similarities between a mouse model and human Alzheimer's.

21 Apr 2012

BuruliVac project getting closer to a vaccine

During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice.

19 Apr 2012

Study explains why some people develop kidney stones and others do not

Kidney stones strike an estimated 1 million Americans each year, and those who have experienced the excruciating pain say it is among the worst known to man (or woman).

19 Apr 2012

Study demonstrates how Parkinson's disease protein can spread in patient's brain

Last year, researchers from the Perelman School of Medicine at the University of Pennsylvania found that small amounts of a misfolded brain protein can be taken up by healthy neurons, replicating within them to cause neurodegeneration. The protein, alpha-synuclein (a-syn), is commonly found in the brain, but forms characteristic clumps called Lewy bodies, in neurons of patients with Parkinson's disease (PD) and other neurodegenerative disorders.

18 Apr 2012

Genetically modified mouse mimics key features of Charcot-Marie-Tooth disease

A team of scientists from the University of Missouri created a genetically modified mouse that mimics key features of Charcot-Marie-Tooth disease, an inherited neuromuscular disease affecting approximately 150,000 people in the United States.

18 Apr 2012

New study describes therapeutic approach to halt cancer progression

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

17 Apr 2012

Two related enzymes play a key role in development of T-ALL

Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.

17 Apr 2012

New compound reverses major symptoms associated with FXS

A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.

12 Apr 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

9 Apr 2012

Mouse Model News and Research

Biosynthetic polyphenol may improve cognitive function in Alzheimer's disease patients

Lenalidomide and SNS01-T combination effective against multiple myeloma

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cedars-Sinai scientist receives ALS Association Golden West Chapter Commitment to a Cure Award

Kras gene triggers metabolic changes that fuel cancer cells

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

Beta cells from genetically modified pigs can effectively restore pancreas function

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Study shows how cocaine changes the shape and size of neuron rewards in mouse model

First study to quantify effects of AD plaques on brain networks in animal model

BuruliVac project getting closer to a vaccine

Study explains why some people develop kidney stones and others do not

Study demonstrates how Parkinson's disease protein can spread in patient's brain

Genetically modified mouse mimics key features of Charcot-Marie-Tooth disease

New study describes therapeutic approach to halt cancer progression

Two related enzymes play a key role in development of T-ALL

New compound reverses major symptoms associated with FXS

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News